Granted, investors are rightfully a little jumpy, but a three-month extension of the Food and Drug Administration's review doesn't seem like that big of a deal. The FDA granted Eylea a priority review, which means the agency plans to complete its review in six months instead of the standard 10 months.
According to Regeneron, more than 50% of drugs given priority review end up having their review extended beyond the six-month goal. It happened to Pfizer's
Nor does that seem to be the case with Eylea. The delay appears to stem from the sheer volume of data about the manufacturing of the drug that Regeneron had to submit and the fact that the agency received the data in the last three months of the review cycle. There haven't been any changes to manufacturing, and Regneron already has a drug on the market, which should give investors confidence that the delay isn't a sign that manufacturing will hold up an approval.
It just appears that the shortened review time lowered the threshold of what's considered a major enough amendment to justify extending the review. If Eylea had been given a standard review, the FDA might have had enough time to review the new data without an extension. The good news is that the original six months plus an additional three months is less than the standard 10 months, so Regeneron is still coming out ahead.
You can keep track of Regeneron as it tries to get Eylea approved by adding it The Fool's free My Watchlist service. Start keeping track of all our Foolish analysis on Regeneron.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.